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ReviewEvery day, more than 1 million people are newly infected
with sexually transmitted infections (STIs) that can lead
to morbidity, mortality, and an increased risk of human
immunodeficiency virus (HIV) acquisition. Existing pre-
vention and management strategies, including behavior
change, condom promotion, and therapy have not re-
duced the global incidence and prevalence, pointing to
the need for novel innovative strategies. This review
summarizes important issues raised during a satellite
session at the first HIV Research for Prevention (R4P)
conference, held in Cape Town, on October 31, 2014. We
explore key STIs that are challenging public health to-
day, new biomedical prevention approaches including
multipurpose prevention technologies (MPTs), and the
scientific and regulatory hurdles that must be overcome
to make combination prevention tools a reality.
Evolving epidemiology of STIs: approaching new
technologies to prevent them
HIV, other STIs, and unintended pregnancy are global
health crises that together affect hundreds of millions of
women and men worldwide. These health concerns share a
common means of exposure, which is important to recog-
nize when planning for prevention and care services be-
cause there is great benefit to addressing them jointly
through MPTs (Box 1).
MPTs are new, all-in-one tools being developed to pro-
tect against HIV, other STIs, and, in some cases, unintend-
ed pregnancy. Much of the work on MPTs to date has
focused on unintended pregnancy and HIV, but there
are important reasons for ensuring that other STIs are
addressed as well (Box 2).
The prevalence of STIs represents a significant public
health burden, and curable STIs are on the rise (Figure 1)0966-842X/
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Asia, numbers of viral STIs such as herpes simplex virus
2 (HSV-2) and human papillomaviruses (HPV) continue to
increase, and fear of these appears to be higher than fear of
HIV acquisition [http://www.who.int/reproductivehealth/
publications/rtis/stisestimates/en/]. Maternal and child
health, mortality, and morbidity, as well as HIV preva-
lence, are also significant concerns in both Sub-Saharan
Africa and South East Asia [http://www.who.int/
reproductivehealth/publications/monitoring/maternal-
mortality-2013/en/].
Infections with sexually transmitted pathogens other
than HIV, as well as persistent reproductive tract infec-
tions, such as bacterial vaginosis, impose an enormous
burden on morbidity and mortality in both resource-
constrained and developed countries. They directly im-
pact on quality of life, reproductive health, and child
health, and augment the risk of acquiring and transmit-
ting HIV [1] or alter the course of other infections. As
examples, HIV-positive women and men are more likely
to have oncogenic HPV types and develop cervical or anal
intraepithelial neoplasias [2], have higher HIV plasma
viral load with HSV-2 seropositivity [3], and decreased
HIV-1 shedding in cervicovaginal lavages due to STI
treatment [4].
Despite their common route of transmission, STIs are a
diverse group of infections with multiple different causa-
tive agents. These can be differentiated into viral infections
(e.g., HIV, HSV, HPV, or hepatitis B), bacterial infections
(e.g., gonococcal, chlamydial, or syphilis) or protista infec-
tions (e.g., trichomoniasis). This is an important concept
because the active agent necessary to control and prevent
each infection may be very different based on the patho-
gen(s) involved [5]. The combination of indications may
vary by prevalence of infections seen in differing geograph-
ic locations around the world. The next sections will review
some of the STIs (other than HIV) that were discussed at
the satellite session at HIVR4P, strategies to prevent
them, and the potential to combine multiple active agents
into one delivery method for broad protection not only
against STIs but also against unintended pregnancy.Trends in Microbiology, July 2015, Vol. 23, No. 7 429
Box 2. STI key factsa
 >1 million people acquire a STI every day.
 >530 million people are infected with HSV-2, with an incidence
rate of 20 million cases annually.
 >290 million women are infected with HPV.
 500 million people become ill with curable STIs every year.
 Some STIs can increase the risk of HIV acquisition or transmis-
sion.
 Some STIs can negatively impact upon the course of HIV
infection.
Box 1. Qualities of ideal MPTs
 Represent the next generation of measures for STI control.
 Be customized for the infections in a targeted geographic area.
 Control various STIs.
 Control one or more STIs and reduce unintended pregnancies.
 Result in multi-faceted, positive outcomes.
aModified from WHO Fact Sheet 110 [http://www.who.int/mediacentre/factsheets/
fs110/en/].
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HSV continues to be a global health concern in its own
right, but also in conjunction with HIV (Box 2) [6]. In
developed countries, HSV-1 has emerged as the principal
cause of genital disease, with a prevalence at 54% of HSV-1
cases in the USA, whereas HSV-2 predominates globally.
Both HSV serotypes are lifelong, persistent infections.
Notably, HSV-2 infection in Sub-Saharan Africa (70%
prevalence of HSV-2 cases) could increase HIV-1 acquisi-
tion and further spread [6–8]. Furthermore, HSV-2/HIV-1
co-infected individuals tend to have more severe herpetic
lesions and increased HSV-2 shedding [9]. These findings,
combined with the absence of any approved prophylactic
drug and recent vaccine failures, highlight the importance
of developing new HSV prevention strategies as a public
health priority [10].
Tenofovir (TFV) and its prodrug tenofovir disoproxil
fumarate (TDF), which function as reverse transcriptase
inhibitors (RTI) after being converted by cellular kinases to
TFV-diphosphate, are being evaluated for prevention of
HIV. These drugs do not require viral kinases for phos-
phorylation and, surprisingly, recent studies suggest that
TFV-DP may provide partial protection against HSV. TFV
1% gel (Table 1) reduced HSV-2 incidence by 51% in women
applying the product before and after sex (BAT24 dosing)
in the CAPRISA-004 pre-exposure prophylaxis (PrEP) trial
[11]. A 30% reduction in HSV-2 was also observed in men
and women using daily oral TFV-based PrEP in a second-
ary analysis [12]. Notably, TDF is 160-fold more active
than TFV against HSV-2, and a 0.3% gel formulation of
TDF provided significantly greater protection than 1%
TFV gel against vaginal HSV-2 in mice [13,14]. The greater
potency of TDF compared to TFV likely reflects the en-
hanced cellular uptake of the former. A polyurethane
intravaginal ring (IVR) designed to deliver TDF recently
completed a Phase I safety study (Table 1), and future
studies should explore whether IVRs [containing either
TDF or acyclovir (ACV)] distribute a sufficient quantity of
drug to sites such as the external genital skin to protect
against HSV acquisition.
Griffithsin (GRFT), a homodimeric lectin derived from
red alga, has been previously reported to bind to gp120 (the
HIV envelope glycoprotein that mediates virus interaction
with cellular receptors and coreceptors) via N-linked man-
nose-rich glycosylation clusters and to have potent anti-
HIV activity in vitro [15,16]. Recently, GRFT was shown to
have modest inhibitory activity against HSV entry, but
was highly potent when added to cultures post-entry and
prevented cell-to-cell spread [17]. These in vitro findings
translated to significant protection against genital herpes
in mice treated with 0.1% GRFT gel (Table 1). Importantly,
the drug retained activity when virus was added in seminal
plasma [17]. The latter findings are distinct from results430obtained with polyanion drugs, such as PRO 2000 and
cellulose sulfate, which lost activity when the virus was
added in seminal plasma, reflecting a competition between
seminal proteins and the drug for the HSV envelope gly-
coproteins [18,19]. By contrast, the MZC gel or MZCL IVR
(Table 1) combines carrageenan (CG) and zinc (in addition
to MIV-150, an anti-HIV non-nucleoside RTI), and showed
potent and durable synergistic anti-HSV-2 activity [20–
22]. This MPT formulation retains antiviral activities
when virus is added in seminal plasma [23].
Poly-[1,4-phenylene-(1-carboxy) methylene] (PPCM),
another candidate microbicide that targets the viral enve-
lope, is currently being evaluated for its anti-HSV and
contraceptive activity, and is a potential candidate for MPT
[24,25]. Thus, both GRFT and PPCM are candidate drugs
for coformulation with TDF/TFV or dapivirine. These com-
binations would target HIV by two different mechanisms
(entry and reverse transcription), and provide activity
against HSV (GRFT and PPCM) and contraception
(PPCM). However, currently these anti-HSV drugs have
been only formulated as gels, and there are challenges to
IVR formulation. In addition, the formulation of GRFT
with CG (in IVR or nanofibers, Table 1) is being explored to
target not only HIV and HSV but also HPV. Combining
ACV with a RTI also holds promise, and it may be easier to
coformulate ACV for IVR delivery (Table 1). An MPT to
block HSV as well as HIV would provide both a direct and
indirect means of HIV prevention and could have a major
impact on the HIV epidemic.
HPV prevention strategies: learning from success and
moving forward
Papillomaviruses, including the HPV types that are the
central cause of cervical cancer, have a unique life cycle in
that virion production only occurs in the stratified squa-
mous epithelium of the skin or mucosal surfaces [26]. Pre-
sumably because infection of the basal cells of the tissue is
necessary, they have also evolved a unique mechanism of
infection. In HPV16 pseudovirion-based mouse and rhesus
macaque cervicovaginal challenge models, mature virions
in solution are unable to directly bind to any epithelial cells
[27,28]. They must first attach to heparan sulfate proteo-
glycans (HSPGs) on the basement membrane that divides
the epithelium from the dermis, at sites in which the
integrity of the epithelium is compromised, such that
the virions have direct access to its surface, and can enter
WHO Region of the Americas
Key:
126 million
WHO African Region
WHO Eastern Mediterranean Region
WHO European Region
WHO SE Asian Region
WHO Western Pacific Region
47 million
128 million
79 million
26 million
93 million
TRENDS in Microbiology 
Figure 1. Global total incidence of selected curable sexually transmitted infections (STIs). The figure shows the incidence of four curable STIs (Trichomonas vaginalis,
Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis) in the six global regions in 2008. The global estimates, especially for these curable STIs, have
relied on the few regions with systematic STI surveillance along with a relatively small number of prevalence studies among discrete populations. The World Health
Organization (WHO) estimates do not include viral STIs, which are often longstanding or lifelong, and comprise a large proportion of prevalent STIs. Modified from WHO
Fact Sheet 110 [http://www.who.int/mediacentre/factsheets/fs110/en/].
Table 1. MPTs in the pipeline that target more than one STI (including HIV)
Product Delivery method APIs Stage Developer Indications
1% TFVa Gel TFV Phase III CONRAD HIV, HSV
TDF IVR TDF Phase I Albert Einstein
College of Medicine
HIV, HSV
MZC (PC-1005) Gel MIV-150, zinc, CG Phase I Population Council HIV, HSV, HPV
TFV IVR TFV Phase I CONRAD HIV, HSV
TFV + LNG IVR TFV, LNG Phase I CONRAD HIV, HSV,
unintended
pregnancy
TFV Vaginal tablet TFV Phase I CONRAD HIV, HSV
Truvada Vaginal tablet TFV, Emtricitabine Phase I CONRAD HIV, HSV
TFV Film TFV Phase I CONRAD,
University of Pittsburgh
HIV, HSV
1%TFV + SILCS diaphragm Gel TFV Phase I CONRAD, PATH HIV, HSV
MZCL IVR MIV-150, zinc, CG, LNG Preclinical Population Council HIV, HSV, HPV,
unintended
pregnancy
Mapp66 (monoclonal antibodies) Film Monoclonal antibodies Preclinical Mapp Biopharmaceutical HIV, HSV
TFV + ACV IVR TFV, ACV Preclinical Auritec Pharmaceuticals HIV, HSV
TFV + IQP-0528 (pyrimidinedione
analog)
IVR TFV, IQP-0528 Preclinical ImQuest BioSciences HIV, HSV
TDF + non-nucleoside reverse
transcriptase inhibitor (NNRTI)
IVR TDF, NNRTI Preclinical Albert Einstein College
of Medicine
HIV, HSV
GRFT Gel GRFT Preclinical University of Louisville,
University of Pittsburgh
HIV, HSV
GRFT CG IVR GRFT, CG Preclinical Population Council HIV, HSV, HPV
GRFT CG Nanofibers GRFT, CG Preclinical Population Council,
University of Washington
HIV, HSV, HPV
PPCM Gel Poly-[1,4-phenylene-
(1-carboxy) methylene]
Preclinical Yaso Biotechnologies HIV, HSV, HPV,
chlamydia,
gonorrhea,
unintended
pregnancy
Stanford Research Institute
two-polymer (SR-2P)
Gel TFV, ACV Preclinical SRI International HIV, HSV
aThe result of the 1% TFV gel Phase III trial was announced at the time of publication of this manuscript. Adherence in the overall study population was too low to show TFV
gel effectiveness in this trial. A reduced glycerin version of this gel is currently in Phase II trial as a potential rectal microbicide.
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Review Trends in Microbiology July 2015, Vol. 23, No. 7basal keratinocytes only after undergoing conformational
changes on the basement membrane [29,30].
Understanding the mechanism of HPV infection can help
to explain the high efficacy of virus-like particles (VLP)-
induced antibodies at preventing HPV infection in clinical
trials of commercial vaccines [31]. The requirement for
sufficient epithelial disruption to expose the basement
membrane implies that the virus must transit through an
increasing gradient of exudated antibodies to reach its
target tissue for attachment. A high level of systemic anti-
bodies, as induced after intramuscular VLP vaccination,
effectively prevents virion binding to the basement mem-
brane in the mouse cervicovaginal challenge model [32]. The
extended time of exposure of the virions to neutralizing
antibodies after basement-membrane binding is likely to
be a crucial factor in the susceptibility of the virus to low
levels of neutralizing antibodies in that it would both pro-
mote accumulation of the antibodies on the virions and
engulfment of the virus/antibody complexes by the phago-
cytic leukocytes attracted to the site of trauma.
The highly-effective HPV vaccines to prevent HPV 6,
11, 16, and 18 (Gardasil and Cervarix), and the recently
approved nonavalent vaccine (Gardasil 9) [33], are with-
out a doubt an excellent start for curbing HPV prevalence,
especially knowing that HPV 16 and 18 are together
responsible for 70% of cervical cancer and >90% of other
non-cervical HPV-related cancers [34]. However, the cur-
rent vaccines have several features that limit their poten-
tial impact. There has been overall low uptake owing to
relatively high cost, lack of provider recommendations,
parental concerns, and limited enthusiasm from some
healthcare providers and public health officials. In
addition, protection is type-restricted, and other HPV
types with anogenital tropism, some which are associated
with increased HIV susceptibility [35,36], need to be
addressed in alternative prevention strategies (such as
broader-spectrum vaccines or microbicides).
The discovery that HSPGs are the crucial initial attach-
ment factors for HPVs, and the development of cell-based
and in vivo assays that supported the HPV vaccine efficacy
[32], led to a targeted screen for potential inhibitors that
might serve as topical microbicides. Several sulfated poly-
saccharides that could potentially compete for HSPG, in-
cluding heparin, inhibited HPV infection [37]. CG,
however, was by far the most potent, with an IC50 of
2 ng/ml, and it was active against a broad spectrum of
genital HPV types. Importantly, it retains high activity in
the presence of seminal plasma [23]. Interestingly, several
commercial sexual lubricants are formulated using CG as
the primary gelling agent. These commercial lubricants
generated inhibition curves that were similar to 1% CG,
exhibiting IC50s of 5 million-fold dilution [37]. CG gels were
also potent inhibitors of cervicovaginal infection in mouse
and rhesus macaque models [22,27,28]. In a clinical trial of
a CG-based microbicide primarily directed at HIV preven-
tion, one-third fewer genital HPV infections were detected
at study exit in the most adherent subgroup of women,
compared to controls [38]. Two randomized placebo-con-
trolled clinical trials evaluating a commercial CG-based
product, Divine #9, as a topical microbicide to specifically
prevent genital HPV infection in young women are now432underway. Developing an MPT with a broad spectrum
anti-HPV agent would overcome the limitations of the
current HPV vaccines as well as the increased HIV sus-
ceptibility in HPV-infected individuals.
Trichomonas vaginalis: curable but not under control
T. vaginalis is more common than Chlamydia trachomatis,
Neisseria gonorrhoeae, and Treponema pallidum com-
bined, making it the most prevalent non-viral STI
[39]. Trichomoniasis infects both men and women through-
out their reproductive lives. Adverse reproductive out-
comes, more severe in women, include premature
rupture of membranes and preterm birth as well as in-
creased risks of acquisition and transmission of HIV. Given
the reproductive consequences, treatment limitations, and
economic impact of this STI, the potential role of MPTs
and/or therapeutic products in preventing this infection
must be pursued.
Systemic treatment for trichomoniasis, commonly re-
ferred to as metronidazole, became available in 1959
[40]. The Centers for Disease Control and Prevention
(CDC) recommended regimes with metronidazole or tini-
dazole that are effective, inexpensive, and widely available
as single-dose therapy. Nevertheless, treatment failure
remains problematic due to noncompliance, reinfection,
or inaccurate diagnosis because symptoms mimic other
STIs and, in addition, there is possible lack of treatment
of sexual partners. Furthermore, resistance of T. vaginalis
to metronidazole treatment is currently found in 2.5–10%
of isolates tested [41], and this argues in favor of new
prevention tools.
Potential prevention strategies for T. vaginalis infec-
tions include development of a vaccine or the application of
microbicides, preferably in MPTs. Vaccine development for
humans has been hampered by a lack of understanding of
the host immune response to T. vaginalis infections. Only
two vaccines have progressed to clinical trials in the past
50 years. Neither candidate proved to be effective. Re-
search continues as we learn more about the surface
proteins that might be viable targets for a vaccine.
In the absence of a vaccine, others are developing MPTs
for prevention of non-ulcerative STIs including T.
vaginalis. The HPTN 035 Phase II/IIB safety and efficacy
study of vaginal microbicides recently evaluated BufferGel
and 0.5% PRO 2000 for prevention of T. vaginalis, C.
trachomatis, and N. gonorrhoeae. Regrettably, neither
candidate microbicide had any protective effect against
trichomoniasis, chlamydia, or gonorrhea [42].
The lack of good animal models for T. vaginalis has
made it difficult to conduct standardized studies to support
microbicide and vaccine development. While a variety of
animals have been evaluated as potential models [43], the
mouse is the most frequently used species. The modified
mouse model has been used extensively in both immuni-
zation and MPT prevention experiments. This model uses
young mice pretreated with estradiol, to promote initial
infectivity of T. vaginalis, and also vaginally pre-colonizes
with lactobacilli before challenge with vaccine candidates
[44] or topical microbicide candidates [45]. The murine
model has shown limited utility in predicting clinical
efficacy.
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a suitable nonhuman primate model for T. vaginalis infec-
tions. The pigtailed macaque is naturally susceptible to
human strains of T. vaginalis, hosts lactobacilli in its
vagina, has a vaginal pH of 5.5–8.0, and sustains infection
for up to 5 weeks without any pretreatment required to
initiate, enhance, or sustain infection. The pigtailed ma-
caque also responds to metronidazole treatment, and signs
of pathogenesis have been colposcopically documented
[46], making it a promising step forward for testing pre-
vention tools against T. vaginalis.
Research to control the spread of T. vaginalis, the
world’s most common, non-viral STI, continues to lag.
Applying new knowledge and using new approaches, pref-
erably within the context of MPTs, may provide opportu-
nities to effectively reduce the spread of T. vaginalis.
Developing all-in-one technologies to target multiple
STIs and unintended pregnancy
MPTs have been primarily designed as woman-initiated
products (although some formulations can be used by men)
that simultaneously reduce the risk of the sexual acquisi-
tion/transmission of HIV, other bacterial, viral, or protista
STIs (especially those that increase the risk of HIV acqui-
sition/transmission), and unintended pregnancy.
MPTs can potentially fill significant unmet sexual and
reproductive health needs. In addition, compelling economic
and practical arguments for MPT development include
greater efficiency in terms of cost, access, and delivery of
sexual and reproductive health (SRH) products, and in-
creased demand for one product type to achieve uptake of
a second (e.g., effective contraception might attract women
to use products that also target HIV and other STIs).
There is consensus that MPTs are worth pursuing [47]
[http://resource.cami-health.org/resources/ipsos.php]
[http://resource.cami-health.org/documents/2012SAWG-
Report-FinalReport.pdf], but there are no objective and(A) (B) (
(E) (F) (
Figure 2. Multipurpose prevention technology (MPT) delivery devices. (A) Male and fe
rings. (F) Nanofibers (photograph courtesy of A. Steger and K.A. Woodrow, University o
diaphragm (photograph courtesy of PATH, Seattle, WA, USA. All rights reserved). (H) V
VA, USA). Images (A, B, D, E) by Julie Sitney (Population Council).quantitative data regarding the best mix of indications
and delivery devices (Figure 2) to pursue. In addition, the
best mix of indications may vary in different regions of the
world based on local patterns of infections and contracep-
tive need as well as user-related social and behavioral
dimensions [48]. Based on survey data collected, the Ini-
tiative for Multipurpose Prevention Technologies and the
Coalition Advancing Multipurpose Innovations (IMPT/
CAMI) propose sustained release devices (e.g., IVRs),
long-acting injectables, and on-demand/pericoital products
(e.g., films and gels) as the highest priorities [http://
mpts101.org/mpt-database].
Because MPT development has evolved from HIV-tar-
geting products, most MPT developers are initially focus-
ing on familiar territory: pursuing indications, active
pharmaceutical ingredients (APIs), and delivery devices
with which they have the most experience or for which
there is a significant body of literature [e.g., Levonorgestrel
(LNG) as the contraceptive] (Table 1). Importantly, MPT
development will be informed by testing these early-phase
MPTs in rigorous clinical trials designed to identify the
best candidates.
This general strategy makes sense initially because the
perceived/much-discussed complexity and additional chal-
lenges of MPT product development can be more easily
understood and overcome using experience derived from
non-MPT products. However, in the long run we will need
to take a different approach, moving beyond prioritizing
delivery options and working in familiar territory to decid-
ing which specific indications, API combinations, and de-
livery devices make the most sense – based on objective
and quantitative criteria such as impact and value (in
economic and human terms) of the intervention, market
size, and potential return on investment [important to both
manufacturers and the non-governmental organization
(NGO) community], cost of the MPT, and the likelihood
of success (risk mitigation).C) (D)
G) (H)
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f Washington, Seattle, WA, USA). (G) SILCS (silicone barrier contraceptive device)
aginal tablet (photograph courtesy of M. Clark and D. Friend, CONRAD, Arlington,
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Box 3. Outstanding questions
 How can the community inform MPT product development
investment and effort from the perspective of hypothetical
justifications?
 What is the best and most-affordable approach and design to test
MPTs in Phase III clinical trials?
 How can the community assist in adding the concept of value-
added product into the cost-effectiveness equation?
 What are the best objective criteria to decide which indications,
devices, and API combinations to prioritize?
 How can the public health community best inform MPT devel-
opers as to their optimal requirements for MPTs?
 How can MPT developers work together and with donors and
regulators to accelerate MPT development?
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The regulatory process for MPT products will involve
additional challenges in comparison to single-indication
products. Because MPTs will target at least two of multiple
possible indications, the development and licensure pro-
cess will involve multiple groups within the relevant reg-
ulatory agencies. With the Food and Drug Administration
(FDA), the regulatory process will involve multiple groups
within the Center for Drug Evaluation and Research
(CDER). If the MPT also involves a drug delivery device,
interactions with the Center for Devices and Radiological
Health will also be required. In addition to the interactions
with a stringent regulatory authority such as the FDA or
the European Medicines Agency (EMA), MPTs will also
likely need to go through WHO prequalification, as well as
local country regulatory authority review. Further compli-
cations may arise depending on the status of the compo-
nent drugs included in the MPT. For example, the process
and requirements for MPTs with APIs that have previous-
ly been approved by the authority for related indications
[e.g., approved antiretroviral (ARV) drugs for HIV treat-
ment] may be simpler than for a product that includes
multiple experimental drug entities.
There are several unique issues that will need to be
addressed from a regulatory perspective, particularly for
MPTs that are designed to prevent HIV infection and unin-
tended pregnancy. For example, particular ARV products
can impact on the metabolism of hormonal contraceptive
(HC) agents, resulting in decreased plasma levels and po-
tentially reducing the contraceptive efficacy [49–51]. Thus,
MPTs will need careful evaluation of drug–drug interac-
tions. In addition, observational data from several HIV
prevention product studies have shown a potential en-
hanced risk of HIV infection in women using particular
HC products [52]. Therefore, the impact of HC components
in MPT products on HIV transmission risk will also be an
issue of interest to regulatory agencies. An additional set of
safety issues for ARV-based MPTs will be the risk of reduced
efficacy against drug-resistant virus and the risk of selection
for resistance in HIV-positive women who use an MPT.
Perhaps the most significant regulatory challenges will
concern the design and implementation of clinical efficacy
studies for MPTs. Adherence issues observed in HIV pre-
vention product trials [53–55] will certainly need to be
addressed in MPT trials. Another challenge will be in
determining the control products in these trials, or if oral
pre-exposure prophylaxis (PrEP) will need to be incorpo-
rated into these trials. Trial design will also need to
consider the local standard of care with regard to use
and acceptance of oral PrEP [56,57] [http://www.proud.
mrc.ac.uk/]. It is also not known if superiority or non-
inferiority design studies will be required, or what the
comparator product would be. Lastly, it is not clear if
bioequivalence-based regulatory strategies will be viable.
Interaction with regulatory agencies on these and addi-
tional issues will be a crucial element of all MPT develop-
ment plans.
Concluding remarks
This review elaborates on the importance of targeting
different STIs in MPTs, with particular emphasis on434non-curable STIs, while also acknowledging the extreme
relevance of preventing unintended pregnancy in these
potential combination products. There are hypothetical
advantages to MPTs: increased demand/uptake for HIV
prevention in MPTs versus HIV prevention-only products;
incremental increase in adherence resulting in cost sav-
ings; efficiencies in delivery and access; policy support for
MPT in relevant parts of the world and procurement bodies
purchasing MPTs. It is important to demonstrate along the
way that those perceived advantages are true, and that is
worth the investment in time and resources to advance into
Phase III clinical trials and beyond.
MPTs need to be carefully conceived in the context of the
entire breath of regulatory complexities and risks that will
potentially apply. The use of more than one drug, novel
devices, potential drug interactions, and clinical trials
(design and adherence) are some of the most complicated
issues that MPT developers will face in satisfying regula-
tory requirements. We need to inform our early product
decisions by carefully considering the requirements that
will arise in later stages of development, such that we
advance the most promising candidates.
The MPT field at present is heavily reliant on the public
health and NGO communities for support. The limits to
funding emphasize the need to design affordable but com-
plex Phase I trials that will inform not only on MPT safety
but also potential efficacy, such as post-coital PK studies
using high-risk populations. In addition, it would benefit
the MPT field to work closely and collaboratively to share
findings, avoid duplications, and ensure that MPTs with
high quality, impact, and value are based on sound scien-
tific principles and are available in the shortest time
possible [58].
MPT developers need to understand where the diseases
are, what the incidence rates are, and what the unmet
medical needs are – to then be able to elaborate the best
strategies to develop a particular combination that will
finally reach a receptive market. Public health communi-
ties and end-users may also look closely into pricing targets
for MPTs, trying to achieve the lowest possible price with-
out asking for impossible goals or missing the advantages
that these technologies may bring in terms of cost, access,
and delivery.
There are many outstanding questions (Box 3) to MPT
development, but the benefits of a safe and effective MPT
will overshadow all the hurdles that must be overcome
[59]. MPTs could be feasible (from a regulatory point of
Review Trends in Microbiology July 2015, Vol. 23, No. 7view), and several examples of multipurpose vaccines
[measles, mumps and rubella (MMR); diphtheria, tetanus,
and pertussis (DTP); pentavalent (DTaP, IPV, and Hib);
and hexavalent (DTaP, IPV, Hib, and HBV)] show us that
is not impossible to reach our common goal: protect those
most in need of MPTs for improved sexual and reproduc-
tive health.
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